RESULTS	Multivariate analysis of PI and histopathologic and clinical features showed the PI ( P = 0.002 ) and the pretreatment serum prostate-specific antigen level ( P = 0.003 ) to be significant prognostic markers of failure in the neoadjuvant group .\